SOLENO THERAPEUTICS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for SOLENO THERAPEUTICS INC (SLNO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are SLNO insiders buying or selling?
In the last 12 months, SOLENO THERAPEUTICS INC insiders reported 0 open-market purchases ($0) and 2 sales ($429.3K) — net selling of $429.3K. Since May 2018, Trabud has recorded 95 Form 4 filings for SLNO: 25 buys ($66.3M) and 70 sells ($337.6M).
Source: SEC EDGAR Form 4
Key Statistics (May 2018 – Apr 1, 2026)
Total Form 4 filings
95
SEC EDGAR
Insider filers
18
Insider buys (25)
$66.3M
Insider sells (70)
$337.6M
Insider sentiment
Net sellingNet insider flow of $271.3M in net selling since May 2018, and $429.3K in net selling over the last 12 months.
Recent SLNO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | Meredith Manning | Chief Commercial Officer | Sale | 7.5K | $30.44 | $229.0K | SEC ↗ |
| Apr 1, 2026 | Michael F. Huang | Sr. VP of Clinical Development | Sale | 6.6K | $30.44 | $200.4K | SEC ↗ |
| Jul 3, 2025 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 3.8K | $82.76 | $317.0K | SEC ↗ |
| Jun 26, 2025 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 266 | $84.25 | $22.4K | SEC ↗ |
| Apr 2, 2025 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 3.8K | $70.11 | $265.2K | SEC ↗ |
| Mar 31, 2025 | Matthew Pauls | Director | Sale | 5.9K | $71.55 | $424.8K | SEC ↗ |
| Mar 31, 2025 | Kristen Yen | Officer title: SVP Global Clinical Operations and Patient Advocacy | Sale | 95.5K | $66.77 | $6.4M | SEC ↗ |
| Mar 31, 2025 | Meredith Manning | Chief Commercial Officer | Sale | 45.2K | $67.28 | $3.0M | SEC ↗ |
| Mar 31, 2025 | James H Mackaness | CHIEF FINANCIAL OFFICER | Sale | 90.6K | $69.44 | $6.3M | SEC ↗ |
| Mar 31, 2025 | Michael F. Huang | Sr. VP of Clinical Development | Sale | 14.6K | $69.51 | $1.0M | SEC ↗ |
| Mar 31, 2025 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 156.3K | $68.51 | $10.7M | SEC ↗ |
| Mar 31, 2025 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | Sale | 699.1K | $67.62 | $47.3M | SEC ↗ |
| Mar 28, 2025 | Vivo Opportunity, LLC | 10% Owner | Sale | 1.8M | $67.87 | $124.4M | SEC ↗ |
| Jan 7, 2025 | Kristen Yen | Officer title: Senior Vice President, Clinical Operations | Sale | 4.9K | $45.78 | $222.5K | SEC ↗ |
| Jan 7, 2025 | James H Mackaness | CHIEF FINANCIAL OFFICER | Sale | 7.9K | $45.78 | $360.5K | SEC ↗ |
| Jan 7, 2025 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 3.0K | $45.78 | $138.7K | SEC ↗ |
| Jan 7, 2025 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | Sale | 21.1K | $45.78 | $965.5K | SEC ↗ |
| Oct 3, 2024 | Kristen Yen | Officer title: Senior Vice President, Clinical Operations | Sale | 3.1K | $49.43 | $153.6K | SEC ↗ |
| Oct 3, 2024 | James H Mackaness | CHIEF FINANCIAL OFFICER | Sale | 8.1K | $49.43 | $399.2K | SEC ↗ |
| Oct 3, 2024 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 3.1K | $49.43 | $153.6K | SEC ↗ |
| Oct 3, 2024 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | Sale | 21.6K | $49.43 | $1.1M | SEC ↗ |
| Aug 30, 2024 | Kristen Yen | Officer title: Senior Vice President, Clinical Operations | Sale | 10.7K | $47.43 | $507.7K | SEC ↗ |
| Aug 30, 2024 | James H Mackaness | CHIEF FINANCIAL OFFICER | Sale | 13.5K | $47.43 | $641.8K | SEC ↗ |
| Aug 30, 2024 | Patricia C Hirano | Officer title: Senior Vice President, Regulatory Affairs | Sale | 10.7K | $47.43 | $507.7K | SEC ↗ |
| Aug 30, 2024 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | Sale | 115.0K | $47.43 | $5.5M | SEC ↗ |
Showing the 25 most recent of 95 Form 4 filings for SOLENO THERAPEUTICS INC.
Most active SLNO insiders
- Patricia C Hirano14 filings
- Bhatnagar Anish12 filings
- James H Mackaness12 filings
- Kristen Yen11 filings
- Jack W Schuler9 filings
Ask anything about SLNO insider activity
Use Trabud's AI agent to query SOLENO THERAPEUTICS INC's Form 4 history in plain English — "Show me SLNO CEO purchases this year" or compare it against any other ticker.
Open the AI agentSLNO insider trading FAQ
Are SOLENO THERAPEUTICS INC insiders buying or selling?
In the last 12 months, SOLENO THERAPEUTICS INC insiders reported 0 open-market purchases ($0) and 2 sales ($429.3K) — net selling of $429.3K. Since May 2018, Trabud has recorded 95 Form 4 filings for SLNO: 25 buys ($66.3M) and 70 sells ($337.6M). Over the full record that is net selling of $271.3M.
How many insiders trade SLNO stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for SOLENO THERAPEUTICS INC. The most recent filing was accepted on Apr 1, 2026.
Where does Trabud get SLNO insider trading data?
All SLNO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.